Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine, irinotecan plus bevacizmab for metastatic colorectal cancer

ABSTRACT: Interventions: XELOX plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Oxaliplatin 130mg/m2 day1 Capecitabin 2000mg/m2/day day1-15 Primary outcome(s): ORR;Over response rate Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Metastatic Or Recurrent Colorectal Cancer

PROVIDER: 2626922 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR